which targets integrin β4, a protein linked to various aggressive cancers. The company is advancing this promising cancer ...

The frontrunner of Vincerx’s bioconjugate programs, VIP236, is an SMDC engineered to bind an α v ß 3 integrin adhesion molecule that is abundantly expressed on cancer cells and activated tumor ...